Nykode Therapeutics ASA (NYKD) — Capital Reinvestment Ratio
Latest as of March 2022:
0.15x
Nykode Therapeutics ASA (NYKD) has a Capital Reinvestment Ratio of 0.15x as of March 2022, meaning it reinvests 0% of its operating cash flow (Nkr96.14 Million) in capital expenditures (Nkr14.06 Million). See Nykode Therapeutics ASA free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.15x
Capex / Operating Cash Flow
Operating Cash Flow
Nkr96.14 Million
NOK
Capital Expenditures
Nkr14.06 Million
NOK
Data as of
Mar 2022
Most recent filing
Nykode Therapeutics ASA Capital Reinvestment Ratio (2020–2021)
This chart tracks Nykode Therapeutics ASA's Capital Reinvestment Ratio across 2 annual periods.
Annual Capital Reinvestment Ratio for Nykode Therapeutics ASA (2020–2021)
Year-by-year Capital Reinvestment Ratio for Nykode Therapeutics ASA from 2020 to 2021. For live market cap and broader valuation context, see market value of Nykode Therapeutics ASA.
| Year | Reinvestment Ratio | Operating CF (NOK) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 0.75x | Nkr1.16 Million | Nkr871.00K | ▲ +137214.0% |
| 2020 | 0.00x | Nkr180.27 Million | Nkr99.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow